2023
Early Detection and Prognostic Assessment of Cutaneous Melanoma
Kashani-Sabet M, Leachman S, Stein J, Arbiser J, Berry E, Celebi J, Curiel-Lewandrowski C, Ferris L, Grant-Kels J, Grossman D, Kulkarni R, Marchetti M, Nelson K, Polsky D, Seiverling E, Swetter S, Tsao H, Verdieck-Devlaeminck A, Wei M, Bar A, Bartlett E, Bolognia J, Bowles T, B. K, Chu E, Hartman R, Hawryluk E, Jampel R, Karapetyan L, Kheterpal M, Lawson D, Leming P, Liebman T, Ming M, Sahni D, Savory S, Shaikh S, Sober A, Sondak V, Spaccarelli N, Usatine R, Venna S, Kirkwood J. Early Detection and Prognostic Assessment of Cutaneous Melanoma. JAMA Dermatology 2023, 159: 545-553. PMID: 36920356, PMCID: PMC11225588, DOI: 10.1001/jamadermatol.2023.0127.Peer-Reviewed Original ResearchConceptsRisk-stratified approachCutaneous melanomaGEP scorePrognostic assessmentGene expression profile testingMelanoma screeningEarly detectionLow-risk histologyNegative nodal statusDelphi consensus methodReflectance confocal microscopyNodal statusSentinel lymphAdvanced melanomaHistologic featuresScreening eventsScreening practicesConsensus statementConsensus recommendationsSkin lesionsDermoscopic examinationGEP testingConsensus conferenceMelanocytic skin lesionsClinical setting
2001
Unusual leucodermas
Bolognia J. Unusual leucodermas. Journal Of The European Academy Of Dermatology And Venereology 2001, 15: 386-387. PMID: 11763374, DOI: 10.1046/j.1468-3083.2001.00318.x.Commentaries, Editorials and Letters
1999
Follow‐up recommendations for patients with American Joint Committee on Cancer Stages I–III malignant melanoma
Poo‐Hwu W, Ariyan S, Lamb L, Papac R, Zelterman D, Hu G, Brown J, Fischer D, Bolognia J, Buzaid A. Follow‐up recommendations for patients with American Joint Committee on Cancer Stages I–III malignant melanoma. Cancer 1999, 86: 2252-2258. PMID: 10590365, DOI: 10.1002/(sici)1097-0142(19991201)86:11<2252::aid-cncr12>3.0.co;2-q.Peer-Reviewed Original ResearchConceptsCancer stage IAmerican Joint CommitteePatient education programStage IYale Melanoma UnitSurveillance scheduleSymptomatic recurrenceMelanoma UnitSurveillance examinationsJoint CommitteeOverall survival rateStage of diseaseDetection of recurrenceAsymptomatic recurrenceAsymptomatic patientsDistant recurrenceLocoregional recurrenceHazard ratioDisease recurrenceInitial visitMore recurrencesMost recurrencesLate recurrenceMelanoma patientsRecurrence group